相关实验视频

Updated: Jul 15, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

扩散型大B细胞淋巴瘤的基因亚型引导免疫化学疗法:随机的GUIDANCE-01试验

Mu-Chen Zhang¹, Shuang Tian¹, Di Fu¹

¹Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

|September 29, 2023

概括

与标准R-CHOP治疗相比,新诊断的扩散性大B细胞淋巴瘤 (DLBCL) 患者接受向治疗R-CHOP-X治疗,显示出明显改善的反应和生存率.

科学领域:

血液学血液学血液学
在瘤学瘤学.
遗传学是一个遗传学.

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 是一种侵略性的非霍奇金淋巴瘤.
像R-CHOP这样的当前治疗方法存在局限性,需要改进治疗策略.
基因亚型化和理解瘤微环境对于DLBCL个性化医学至关重要.

研究的目的:

评估R-CHOP与向药物 (R-CHOP-X) 结合的疗效和安全性,与R-CHOP单独用于新诊断的中等或高风险DLBCL.
评估基因亚型在指导治疗选择中的作用.
为了验证简化的遗传亚型算法和淋巴瘤微环境亚型.

主要方法:

GUIDANCE-01,一个随机的II期临床试验 (NCT04025593).
128名新诊断的DLBCL患者被随机分配1:1接受R-CHOP-X或R-CHOP.
后期RNA测序用于验证遗传和微环境亚型.

主要成果:

与R-CHOP相比,R-CHOP-X显示出明显更高的完整响应率 (88%对66%,p=0.003) 和整体响应率 (92%对73%,p=0.005).
使用R-CHOP-X显著改善了两年无进展生存率 (88%对63%,p<0.001).
在R-CHOP-X手臂中,两年总生存率也更高 (94%对77%,p=0.001).

结论:

R-CHOP-X是一种有效且安全的基于机制的针对新诊断的DLBCL量身定制疗法.
针对遗传和微环境变化,可以改善患者的治疗结果.
简化的遗传亚型算法得到了验证,对于指导DLBCL治疗是有用的.

关键词:

扩散大的B细胞淋巴瘤.遗传亚型遗传亚型遗传亚型淋巴瘤微环境是一个微环境.随机的临床试验随机的临床试验有针对性的治疗.

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...